Therapeutic effects of artesunate in hepatocellular carcinoma: Repurposing an ancient antimalarial agent

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 8, 2014, Pages 861-870

  Vandewynckel, Yves Paul ^a   Laukens, Debby ^a   Geerts, Anja ^a   Vanhove, Chris ^b,d   Descamps, Benedicte ^b   Colle, Isabelle ^a   Devisscher, Lindsey ^a   Bogaerts, Eliene ^a   Paridaens, Annelies ^a   Verhelst, Xavier ^a   Van Steenkiste, Christophe ^a   Libbrecht, Louis ^a   Lambrecht, Bart N ^c,d,e   Janssens, Sophie ^c,d,e   Van Vlierberghe, Hans ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b INFINITY MEDISIP   (Belgium)

^c Department of Respiratory Medicine ^*  (Belgium)

^d GHENT UNIVERSITY   (Belgium)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

angiogenesis inhibitors; ATP binding cassette transporters; HepG2 cells; sorafenib; unfolded protein response

Indexed keywords

ALANINE AMINOTRANSFERASE; ARTESUNATE; ASPARTATE AMINOTRANSFERASE; BREAST CANCER RESISTANCE PROTEIN; CASPASE 3; CHOLINE; DIETHYLNITROSAMINE; DOXORUBICIN; EOSIN; HEMATOXYLIN; LACTATE DEHYDROGENASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; OXYGEN; PIMONIDAZOLE; PLACENTAL GROWTH FACTOR; RETICULIN; SODIUM CHLORIDE; SORAFENIB; TETRAZOLIUM; VASCULOTROPIN; ANTINEOPLASTIC AGENT; ARTEMISININ DERIVATIVE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER GROWTH; CANCER RESISTANCE; CELL DENSITY; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ASSAY; HEPG2 CELL LINE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER CELL CARCINOMA; LIVER TOXICITY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; THERAPY EFFECT; TUMOR VOLUME; UNFOLDED PROTEIN RESPONSE; UPREGULATION; WEIGHT REDUCTION; WESTERN BLOTTING; WST-1 ASSAY; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL DEATH; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; DRUG REPOSITIONING; DRUG RESISTANCE; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL CULTURE; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ARTEMISININS; CARCINOMA, HEPATOCELLULAR; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG REPOSITIONING; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; UNFOLDED PROTEIN RESPONSE;

EID: 84903961880     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000066     Document Type: Article

References (38)

1. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58:593-608.
2. Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996; 83:1219-1222.
3. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908-943.
4. Chen ZS, Tiwari AK. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J 2011; 278: 3226-3245.
5. Moustafa MA, Ogino D, Nishimura M, Ueda N, Naito S, Furukawa M, et al. Comparative analysis of ATP-binding cassette (ABC) transporter gene expression levels in peripheral blood leukocytes and in liver with hepatocellular carcinoma. Cancer Sci 2004; 95:530-536.
6. Borel F, Han R, Visser A, Petry H, van Deventer SJ, Jansen PL, Konstantinova P. Réseau Centre de Ressources Biologiques Foie (French Liver Biobanks Network), France. Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 2012; 55:821-832.
7. Bonin S, Pascolo L, Crocé LS, Stanta G, Tiribelli C. Gene expression of ABC proteins in hepatocellular carcinoma, peraneoplastic tissue, and liver diseases. Mol Med 2002; 8:318-325.
8. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
9. Crespo-Ortiz MP, Wei MQ. Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol 2012; 2012:247597.
10. Zhang CZ, Zhang H, Yun J, Chen GG, Lai PB. Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem Pharmacol 2012; 83:1278-1289.
11. Haynes RK. From artemisinin to new artemisinin antimalarials: biosynthesis, extraction, old and new derivatives, stereochemistry and medicinal chemistry requirements. Curr Top Med Chem 2006; 6:509-537.
12. Pascale RM, De Miglio MR, Muroni MR, Simile MM, Daino L, Seddaiu MA, et al. Transferrin and transferrin receptor gene expression and iron uptake in hepatocellular carcinoma in the rat. Hepatology 1998; 27:452-461.
13. Chen HH, Zhou HJ, Wu GD, Lou XE. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology 2004; 71:1-9.
14. Shuda M, Kondoh N, Imazeki N, Tanaka K, Okada T, Mori K. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J Hepatol 2003; 38:605-614.
15. Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. J Hepatol 2011; 54:795-809.
16. Dong D, Ni M, Li J, Xiong S, Ye W, Virrey JJ, et al. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res 2008; 68:498-505.
17. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011; 334:1081-1086.
18. Szpirer C, Szpirer J. A mouse hepatoma cell line which secretes several serum proteins including albumin and alpha-foetoprotein. Differentiation 1975; 4:85-91.
19. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010; 141:178-190.
20. Heindryckx F, Mertens K, Charette N, Vandeghinste B, Casteleyn C, Van Steenkiste C, et al. Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma. Mol Cancer 2010; 9:219.
21. Heindryckx F, Kuchnio A, Casteleyn C, Coulon S, Olievier K, Colle I, et al. Effect of prolyl hydroxylase domain-2 haplodeficiency on the hepatocarcinogenesis in mice. J Hepatol 2012; 57:61-68.
22. Kuang Y, Salem N, Corn DJ, Erokwu B, Tian H, Wang F, Lee Z. Transport and metabolism of radiolabeled choline in hepatocellular carcinoma. Mol Pharm 2010; 7:2077-2092.
23. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 (Suppl 1):122S-150S.
24. Sun Z, Zhao Z, Li G, Dong S, Huang Z, Ye L, et al. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies. Tumori 2010; 96:90-96.
25. Li G, Chen X, Wang Q, Xu Z, Zhang W, Ye L. The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance. J Huazhong Univ Sci Technolog Med Sci 2007; 27:173-175.
26. Zhu H, Chen XP, Luo SF, Guan J, Zhang WG, Zhang BX. Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells. J Exp Clin Cancer Res 2005; 24:565-574.
27. Efferth T, Kaina B. Toxicity of the antimalarial artemisinin and its derivatives. Crit Rev Toxicol 2010; 40:405-421.
28. Taylor W, Terlouw DJ, Olliaro PL, White NJ, Brasseur P, ter Kuile FO. Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria. Bull World Health Organ 2006; 84:956-964.
29. Aquino I, Tsuboy MS, Marcarini JC, Mantovani MS, Perazzo FF, Maistro EL. Genotoxic evaluation of the antimalarial drugs artemisinin and artesunate in human HepG2 cells and effects on CASP3 and SOD1 gene expressions. Genet Mol Res 2013; 12:2517-2527.
30. Jin M, Shen X, Zhao C, Qin X, Liu H, Huang L, et al. In vivo study of effects of artesunate nanoliposomes on human hepatocellular carcinoma xenografts in nude mice. Drug Deliv 2013; 20:127-133.
31. Zhou HJ, Wang WQ, Wu GD, Lee J, Li A. Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascul Pharmacol 2007; 47:131-138.
32. DellEva R, Pfeffer U, Vené R, Anfosso L, Forlani A, Albini A, Efferth T. Inhibition of angiogenesis in vivo and growth of Kaposis sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol 2004; 68:2359-2366.
33. Ghosh R, Lipson KL, Sargent KE, Mercurio AM, Hunt JS, Ron D, Urano F. Transcriptional regulation of VEGF-A by the unfolded protein response pathway. PloS One 2010; 5:e9575.
34. Wu XZ, Xie GR, Chen D. Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22:1178-1182.
35. Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, et al. Hypoxiamediated sorafenib resistance can be overcome by EF24 through VHLdependent HIF-1α inhibition in hepatocellular carcinoma. Hepatology 2013; 57:1847-1857.
36. Heindryckx F, Coulon S, Terrie E, Casteleyn C, Stassen JM, Geerts A, et al. The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model. J Hepatol 2013; 58:319-328.
37. Ma H, Yao Q, Zhang AM, Lin S, Wang XX, Wu L, et al. The effects of artesunate on the expression of EGFR and ABCG2 in A549 human lung cancer cells and a xenograft model. Molecules 2011; 16: 10556-10569.
38. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142:1264-1273.e1.